

# Global Human Immumoglobulin (PH4) for Intravenous Injection Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G26A768DCD86EN.html>

Date: January 2026

Pages: 175

Price: US\$ 4,480.00 (Single User License)

ID: G26A768DCD86EN

## Abstracts

The global Human Immumoglobulin (PH4) for Intravenous Injection market size is expected to reach \$ 22252 million by 2032, rising at a market growth of 8.1% CAGR during the forecast period (2026-2032).

In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.

Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.

Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.

This report studies the global Human Immumoglobulin (PH4) for Intravenous Injection production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Human Immumoglobulin (PH4) for Intravenous Injection and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Immumoglobulin (PH4) for Intravenous Injection that contribute to its increasing demand across many markets.

### **Highlights and key features of the study**

Global Human Immumoglobulin (PH4) for Intravenous Injection total production and demand, 2021-2032, (Tons)

Global Human Immumoglobulin (PH4) for Intravenous Injection total production value, 2021-2032, (USD Million)

Global Human Immumoglobulin (PH4) for Intravenous Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Tons), (based on production site)

Global Human Immumoglobulin (PH4) for Intravenous Injection consumption by region & country, CAGR, 2021-2032 & (Tons)

U.S. VS China: Human Immumoglobulin (PH4) for Intravenous Injection domestic production, consumption, key domestic manufacturers and share

Global Human Immumoglobulin (PH4) for Intravenous Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Tons)

Global Human Immumoglobulin (PH4) for Intravenous Injection production by Concentration, production, value, CAGR, 2021-2032, (USD Million) & (Tons)

Global Human Immumoglobulin (PH4) for Intravenous Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Tons)

This report profiles key players in the global Human Immumoglobulin (PH4) for Intravenous Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boya-Bio, Beijing Tiantan Biological Products, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Hualan Bio, CTBB, Sinopharm, Nanyue Biopharming, Shanghai RAAS, ADMA Biologics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Immumoglobulin (PH4) for Intravenous Injection market

**Detailed Segmentation:**

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (Tons) and average price (US\$/g) by manufacturer, by Concentration, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Human Immumoglobulin (PH4) for Intravenous Injection Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Human Immumoglobulin (PH4) for Intravenous Injection Market, Segmentation by Concentration:

5%

10%

20%

Global Human Immumoglobulin (PH4) for Intravenous Injection Market, Segmentation by Source Plasma Screening Standard:

Standard-Qualified Plasma

High-Safety Plasma

Special-Indication

Global Human Immumoglobulin (PH4) for Intravenous Injection Market, Segmentation by Production Process:

Cohn-Fractionation

Chromatography-Purified

Ultrafiltration-Refined

Global Human Immumoglobulin (PH4) for Intravenous Injection Market, Segmentation by Application:

Immunodeficiency Disease

Autoimmune Disease

Severe Infectious Disease

### **Companies Profiled:**

Boya-Bio

Beijing Tiantan Biological Products

Guangdong Shuagnlin Bio-pharmacy

Weiguang Biological

Hualan Bio

CTBB

Sinopharm

Nanyue Biopharming

Shanghai RAAS

ADMA Biologics

Grand Shuyang

PAFC

Weiguang Biological Products

Beijing Bohui Innovation Biotechnology

CSL Behring

Takeda

Grifols

Octapharma

Bio Products Laboratory

Kedrion

LFB

GC Biopharma

### **Key Questions Answered:**

1. How big is the global Human Immumoglobulin (PH4) for Intravenous Injection market?
2. What is the demand of the global Human Immumoglobulin (PH4) for Intravenous Injection market?

3. What is the year over year growth of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
4. What is the production and production value of the global Human Immumoglobulin (PH4) for Intravenous Injection market?
5. Who are the key producers in the global Human Immumoglobulin (PH4) for Intravenous Injection market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Human Immumoglobulin (PH4) for Intravenous Injection Introduction
- 1.2 World Human Immumoglobulin (PH4) for Intravenous Injection Supply & Forecast
  - 1.2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021 & 2025 & 2032)
  - 1.2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
  - 1.2.3 World Human Immumoglobulin (PH4) for Intravenous Injection Pricing Trends (2021-2032)
- 1.3 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (Based on Production Site)
  - 1.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021-2032)
  - 1.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2021-2032)
  - 1.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2032)
  - 1.3.4 North America Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
  - 1.3.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
  - 1.3.6 China Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
  - 1.3.7 Japan Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
  - 1.3.8 Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
  - 1.3.9 India Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Human Immumoglobulin (PH4) for Intravenous Injection Major Market Trends

### 2 DEMAND SUMMARY

- 2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Demand (2021-2032)
- 2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region
  - 2.2.1 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region (2021-2026)
  - 2.2.2 World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Forecast by Region (2027-2032)
- 2.3 United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
- 2.4 China Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
- 2.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
- 2.6 Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
- 2.7 South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
- 2.8 ASEAN Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)
- 2.9 India Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032)

### **3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS**

- 3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Manufacturer (2021-2026)
- 3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Manufacturer (2021-2026)
- 3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026)
- 3.4 Human Immumoglobulin (PH4) for Intravenous Injection Company Evaluation Quadrant
- 3.5 Industry Rank and Concentration Rate (CR)
  - 3.5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Industry Rank of Major Manufacturers
  - 3.5.2 Global Concentration Ratios (CR4) for Human Immumoglobulin (PH4) for Intravenous Injection in 2025
  - 3.5.3 Global Concentration Ratios (CR8) for Human Immumoglobulin (PH4) for

## Intravenous Injection in 2025

### 3.6 Human Immumoglobulin (PH4) for Intravenous Injection Market: Overall Company Footprint Analysis

#### 3.6.1 Human Immumoglobulin (PH4) for Intravenous Injection Market: Region Footprint

#### 3.6.2 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint

#### 3.6.3 Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint

### 3.7 Competitive Environment

#### 3.7.1 Historical Structure of the Industry

#### 3.7.2 Barriers of Market Entry

#### 3.7.3 Factors of Competition

### 3.8 New Entrant and Capacity Expansion Plans

### 3.9 Mergers, Acquisition, Agreements, and Collaborations

## 4 UNITED STATES VS CHINA VS REST OF THE WORLD

### 4.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison

#### 4.1.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison (2021 & 2025 & 2032)

#### 4.1.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share Comparison (2021 & 2025 & 2032)

### 4.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison

#### 4.2.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison (2021 & 2025 & 2032)

#### 4.2.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share Comparison (2021 & 2025 & 2032)

### 4.3 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison

#### 4.3.1 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison (2021 & 2025 & 2032)

#### 4.3.2 United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share Comparison (2021 & 2025 & 2032)

### 4.4 United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share, 2021-2026

#### 4.4.1 United States Based Human Immumoglobulin (PH4) for Intravenous Injection

Manufacturers, Headquarters and Production Site (States, Country)

4.4.2 United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)

4.4.3 United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)

4.5 China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share

4.5.1 China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (Province, Country)

4.5.2 China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)

4.5.3 China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)

4.6 Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers and Market Share, 2021-2026

4.6.1 Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (State, Country)

4.6.2 Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value (2021-2026)

4.6.3 Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026)

## **5 MARKET ANALYSIS BY CONCENTRATION**

5.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size Overview by Concentration: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Concentration

5.2.1 5%

5.2.2 10%

5.2.3 20%

5.3 Market Segment by Concentration

5.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2021-2032)

5.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2021-2032)

5.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032)

## **6 MARKET ANALYSIS BY SOURCE PLASMA SCREENING STANDARD**

6.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size  
Overview by Source Plasma Screening Standard: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Source Plasma Screening Standard

6.2.1 Standard-Qualified Plasma

6.2.2 High-Safety Plasma

6.2.3 Special-Indication

6.3 Market Segment by Source Plasma Screening Standard

6.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by  
Source Plasma Screening Standard (2021-2032)

6.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value  
by Source Plasma Screening Standard (2021-2032)

6.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by  
Source Plasma Screening Standard (2021-2032)

## **7 MARKET ANALYSIS BY PRODUCTION PROCESS**

7.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size  
Overview by Production Process: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Production Process

7.2.1 Cohn-Fractionation

7.2.2 Chromatography-Purified

7.2.3 Ultrafiltration-Refined

7.3 Market Segment by Production Process

7.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by  
Production Process (2021-2032)

7.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value  
by Production Process (2021-2032)

7.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by  
Production Process (2021-2032)

## **8 MARKET ANALYSIS BY APPLICATION**

8.1 World Human Immumoglobulin (PH4) for Intravenous Injection Market Size  
Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Immunodeficiency Disease

8.2.2 Autoimmune Disease

8.2.3 Severe Infectious Disease

## 8.3 Market Segment by Application

8.3.1 World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2021-2032)

8.3.2 World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2021-2032)

8.3.3 World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032)

## 9 COMPANY PROFILES

### 9.1 Boya-Bio

9.1.1 Boya-Bio Details

9.1.2 Boya-Bio Major Business

9.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.1.4 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.1.5 Boya-Bio Recent Developments/Updates

9.1.6 Boya-Bio Competitive Strengths & Weaknesses

### 9.2 Beijing Tiantan Biological Products

9.2.1 Beijing Tiantan Biological Products Details

9.2.2 Beijing Tiantan Biological Products Major Business

9.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.2.4 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.2.5 Beijing Tiantan Biological Products Recent Developments/Updates

9.2.6 Beijing Tiantan Biological Products Competitive Strengths & Weaknesses

### 9.3 Guangdong Shuagnlin Bio-pharmacy

9.3.1 Guangdong Shuagnlin Bio-pharmacy Details

9.3.2 Guangdong Shuagnlin Bio-pharmacy Major Business

9.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.3.4 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates

9.3.6 Guangdong Shuagnlin Bio-pharmacy Competitive Strengths & Weaknesses

## 9.4 Weiguang Biological

9.4.1 Weiguang Biological Details

9.4.2 Weiguang Biological Major Business

9.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.4.4 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.4.5 Weiguang Biological Recent Developments/Updates

9.4.6 Weiguang Biological Competitive Strengths & Weaknesses

## 9.5 Hualan Bio

9.5.1 Hualan Bio Details

9.5.2 Hualan Bio Major Business

9.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.5.4 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.5.5 Hualan Bio Recent Developments/Updates

9.5.6 Hualan Bio Competitive Strengths & Weaknesses

## 9.6 CTBB

9.6.1 CTBB Details

9.6.2 CTBB Major Business

9.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.6.4 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.6.5 CTBB Recent Developments/Updates

9.6.6 CTBB Competitive Strengths & Weaknesses

## 9.7 Sinopharm

9.7.1 Sinopharm Details

9.7.2 Sinopharm Major Business

9.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.7.4 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.7.5 Sinopharm Recent Developments/Updates

9.7.6 Sinopharm Competitive Strengths & Weaknesses

## 9.8 Nanyue Biopharming

9.8.1 Nanyue Biopharming Details

9.8.2 Nanyue Biopharming Major Business

9.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.8.4 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.8.5 Nanyue Biopharming Recent Developments/Updates

9.8.6 Nanyue Biopharming Competitive Strengths & Weaknesses

9.9 Shanghai RAAS

9.9.1 Shanghai RAAS Details

9.9.2 Shanghai RAAS Major Business

9.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.9.4 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.9.5 Shanghai RAAS Recent Developments/Updates

9.9.6 Shanghai RAAS Competitive Strengths & Weaknesses

9.10 ADMA Biologics

9.10.1 ADMA Biologics Details

9.10.2 ADMA Biologics Major Business

9.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.10.4 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.10.5 ADMA Biologics Recent Developments/Updates

9.10.6 ADMA Biologics Competitive Strengths & Weaknesses

9.11 Grand Shuyang

9.11.1 Grand Shuyang Details

9.11.2 Grand Shuyang Major Business

9.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.11.4 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

9.11.5 Grand Shuyang Recent Developments/Updates

9.11.6 Grand Shuyang Competitive Strengths & Weaknesses

9.12 PAFC

9.12.1 PAFC Details

9.12.2 PAFC Major Business

9.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

9.12.4 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Production,

## Price, Value, Gross Margin and Market Share (2021-2026)

### 9.12.5 PAFC Recent Developments/Updates

### 9.12.6 PAFC Competitive Strengths & Weaknesses

## 9.13 Weiguang Biological Products

### 9.13.1 Weiguang Biological Products Details

### 9.13.2 Weiguang Biological Products Major Business

### 9.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

### 9.13.4 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

### 9.13.5 Weiguang Biological Products Recent Developments/Updates

### 9.13.6 Weiguang Biological Products Competitive Strengths & Weaknesses

## 9.14 Beijing Bohui Innovation Biotechnology

### 9.14.1 Beijing Bohui Innovation Biotechnology Details

### 9.14.2 Beijing Bohui Innovation Biotechnology Major Business

### 9.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

### 9.14.4 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

### 9.14.5 Beijing Bohui Innovation Biotechnology Recent Developments/Updates

### 9.14.6 Beijing Bohui Innovation Biotechnology Competitive Strengths & Weaknesses

## 9.15 CSL Behring

### 9.15.1 CSL Behring Details

### 9.15.2 CSL Behring Major Business

### 9.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

### 9.15.4 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

### 9.15.5 CSL Behring Recent Developments/Updates

### 9.15.6 CSL Behring Competitive Strengths & Weaknesses

## 9.16 Takeda

### 9.16.1 Takeda Details

### 9.16.2 Takeda Major Business

### 9.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

### 9.16.4 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)

### 9.16.5 Takeda Recent Developments/Updates

- 9.16.6 Takeda Competitive Strengths & Weaknesses
- 9.17 Grifols
  - 9.17.1 Grifols Details
  - 9.17.2 Grifols Major Business
  - 9.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
  - 9.17.4 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
  - 9.17.5 Grifols Recent Developments/Updates
  - 9.17.6 Grifols Competitive Strengths & Weaknesses
- 9.18 Octapharma
  - 9.18.1 Octapharma Details
  - 9.18.2 Octapharma Major Business
  - 9.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
  - 9.18.4 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
  - 9.18.5 Octapharma Recent Developments/Updates
  - 9.18.6 Octapharma Competitive Strengths & Weaknesses
- 9.19 Bio Products Laboratory
  - 9.19.1 Bio Products Laboratory Details
  - 9.19.2 Bio Products Laboratory Major Business
  - 9.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
  - 9.19.4 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
  - 9.19.5 Bio Products Laboratory Recent Developments/Updates
  - 9.19.6 Bio Products Laboratory Competitive Strengths & Weaknesses
- 9.20 Kedrion
  - 9.20.1 Kedrion Details
  - 9.20.2 Kedrion Major Business
  - 9.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
  - 9.20.4 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
  - 9.20.5 Kedrion Recent Developments/Updates
  - 9.20.6 Kedrion Competitive Strengths & Weaknesses
- 9.21 LFB
  - 9.21.1 LFB Details

- 9.21.2 LFB Major Business
- 9.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- 9.21.4 LFB Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
- 9.21.5 LFB Recent Developments/Updates
- 9.21.6 LFB Competitive Strengths & Weaknesses
- 9.22 GC Biopharma
  - 9.22.1 GC Biopharma Details
  - 9.22.2 GC Biopharma Major Business
  - 9.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
  - 9.22.4 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
  - 9.22.5 GC Biopharma Recent Developments/Updates
  - 9.22.6 GC Biopharma Competitive Strengths & Weaknesses

## **10 INDUSTRY CHAIN ANALYSIS**

- 10.1 Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain
- 10.2 Human Immumoglobulin (PH4) for Intravenous Injection Upstream Analysis
  - 10.2.1 Human Immumoglobulin (PH4) for Intravenous Injection Core Raw Materials
  - 10.2.2 Main Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection Core Raw Materials
- 10.3 Midstream Analysis
- 10.4 Downstream Analysis
- 10.5 Human Immumoglobulin (PH4) for Intravenous Injection Production Mode
- 10.6 Human Immumoglobulin (PH4) for Intravenous Injection Procurement Model
- 10.7 Human Immumoglobulin (PH4) for Intravenous Injection Industry Sales Model and Sales Channels
  - 10.7.1 Human Immumoglobulin (PH4) for Intravenous Injection Sales Model
  - 10.7.2 Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors

## **11 RESEARCH FINDINGS AND CONCLUSION**

## **12 APPENDIX**

- 12.1 Methodology
- 12.2 Research Process and Data Source

## 12.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021, 2025 and 2032) & (USD Million)

Table 2. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2021-2026) & (USD Million)

Table 3. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Region (2027-2032) & (USD Million)

Table 4. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2021-2026)

Table 5. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2027-2032)

Table 6. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2021-2026) & (Tons)

Table 7. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Region (2027-2032) & (Tons)

Table 8. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2021-2026)

Table 9. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2027-2032)

Table 10. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2021-2026) & (US\$/g)

Table 11. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Region (2027-2032) & (US\$/g)

Table 12. Human Immumoglobulin (PH4) for Intravenous Injection Major Market Trends

Table 13. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Tons)

Table 14. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption by Region (2021-2026) & (Tons)

Table 15. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Forecast by Region (2027-2032) & (Tons)

Table 16. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Manufacturer (2021-2026) & (USD Million)

Table 17. Production Value Market Share of Key Human Immumoglobulin (PH4) for Intravenous Injection Producers in 2025

Table 18. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Manufacturer (2021-2026) & (Tons)

Table 19. Production Market Share of Key Human Immumoglobulin (PH4) for Intravenous Injection Producers in 2025

Table 20. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturer (2021-2026) & (US\$/g)

Table 21. Global Human Immumoglobulin (PH4) for Intravenous Injection Company Evaluation Quadrant

Table 22. World Human Immumoglobulin (PH4) for Intravenous Injection Industry Rank of Major Manufacturers, Based on Production Value in 2025

Table 23. Head Office and Human Immumoglobulin (PH4) for Intravenous Injection Production Site of Key Manufacturer

Table 24. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Type Footprint

Table 25. Human Immumoglobulin (PH4) for Intravenous Injection Market: Company Product Application Footprint

Table 26. Human Immumoglobulin (PH4) for Intravenous Injection Competitive Factors

Table 27. Human Immumoglobulin (PH4) for Intravenous Injection New Entrant and Capacity Expansion Plans

Table 28. Human Immumoglobulin (PH4) for Intravenous Injection Mergers & Acquisitions Activity

Table 29. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 30. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Production Comparison, (2021 & 2025 & 2032) & (Tons)

Table 31. United States VS China Human Immumoglobulin (PH4) for Intravenous Injection Consumption Comparison, (2021 & 2025 & 2032) & (Tons)

Table 32. United States Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (States, Country)

Table 33. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)

Table 34. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)

Table 35. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2026) & (Tons)

Table 36. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)

Table 37. China Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (Province, Country)

Table 38. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)

Table 39. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)

Table 40. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production, (2021-2026) & (Tons)

Table 41. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)

Table 42. Rest of World Based Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers, Headquarters and Production Site (State, Country)

Table 43. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value, (2021-2026) & (USD Million)

Table 44. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share (2021-2026)

Table 45. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production, (2021-2026) & (Tons)

Table 46. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share (2021-2026)

Table 47. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration, (USD Million), 2021 & 2025 & 2032

Table 48. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2021-2026) & (Tons)

Table 49. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Concentration (2027-2032) & (Tons)

Table 50. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2021-2026) & (USD Million)

Table 51. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration (2027-2032) & (USD Million)

Table 52. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2026) & (US\$/g)

Table 53. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2027-2032) & (US\$/g)

Table 54. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032

Table 55. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2021-2026) & (Tons)

Table 56. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Source Plasma Screening Standard (2027-2032) & (Tons)

Table 57. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard (2021-2026) & (USD Million)

Table 58. World Human Immumoglobulin (PH4) for Intravenous Injection Production

Value by Source Plasma Screening Standard (2027-2032) & (USD Million)

Table 59. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2026) & (US\$/g)

Table 60. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2027-2032) & (US\$/g)

Table 61. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process, (USD Million), 2021 & 2025 & 2032

Table 62. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2021-2026) & (Tons)

Table 63. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Production Process (2027-2032) & (Tons)

Table 64. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2021-2026) & (USD Million)

Table 65. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process (2027-2032) & (USD Million)

Table 66. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2026) & (US\$/g)

Table 67. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2027-2032) & (US\$/g)

Table 68. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032

Table 69. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2021-2026) & (Tons)

Table 70. World Human Immumoglobulin (PH4) for Intravenous Injection Production by Application (2027-2032) & (Tons)

Table 71. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2021-2026) & (USD Million)

Table 72. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application (2027-2032) & (USD Million)

Table 73. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2026) & (US\$/g)

Table 74. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2027-2032) & (US\$/g)

Table 75. Boya-Bio Basic Information, Manufacturing Base and Competitors

Table 76. Boya-Bio Major Business

Table 77. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 78. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share

(2021-2026)

Table 79. Boya-Bio Recent Developments/Updates

Table 80. Boya-Bio Competitive Strengths & Weaknesses

Table 81. Beijing Tiantan Biological Products Basic Information, Manufacturing Base and Competitors

Table 82. Beijing Tiantan Biological Products Major Business

Table 83. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 84. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 85. Beijing Tiantan Biological Products Recent Developments/Updates

Table 86. Beijing Tiantan Biological Products Competitive Strengths & Weaknesses

Table 87. Guangdong Shuagnlin Bio-pharmacy Basic Information, Manufacturing Base and Competitors

Table 88. Guangdong Shuagnlin Bio-pharmacy Major Business

Table 89. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 90. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 91. Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates

Table 92. Guangdong Shuagnlin Bio-pharmacy Competitive Strengths & Weaknesses

Table 93. Weiguang Biological Basic Information, Manufacturing Base and Competitors

Table 94. Weiguang Biological Major Business

Table 95. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 96. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 97. Weiguang Biological Recent Developments/Updates

Table 98. Weiguang Biological Competitive Strengths & Weaknesses

Table 99. Hualan Bio Basic Information, Manufacturing Base and Competitors

Table 100. Hualan Bio Major Business

Table 101. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 102. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

- Table 103. Hualan Bio Recent Developments/Updates
- Table 104. Hualan Bio Competitive Strengths & Weaknesses
- Table 105. CTBB Basic Information, Manufacturing Base and Competitors
- Table 106. CTBB Major Business
- Table 107. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 108. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 109. CTBB Recent Developments/Updates
- Table 110. CTBB Competitive Strengths & Weaknesses
- Table 111. Sinopharm Basic Information, Manufacturing Base and Competitors
- Table 112. Sinopharm Major Business
- Table 113. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 114. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 115. Sinopharm Recent Developments/Updates
- Table 116. Sinopharm Competitive Strengths & Weaknesses
- Table 117. Nanyue Biopharming Basic Information, Manufacturing Base and Competitors
- Table 118. Nanyue Biopharming Major Business
- Table 119. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 120. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 121. Nanyue Biopharming Recent Developments/Updates
- Table 122. Nanyue Biopharming Competitive Strengths & Weaknesses
- Table 123. Shanghai RAAS Basic Information, Manufacturing Base and Competitors
- Table 124. Shanghai RAAS Major Business
- Table 125. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 126. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 127. Shanghai RAAS Recent Developments/Updates
- Table 128. Shanghai RAAS Competitive Strengths & Weaknesses

Table 129. ADMA Biologics Basic Information, Manufacturing Base and Competitors

Table 130. ADMA Biologics Major Business

Table 131. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 132. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 133. ADMA Biologics Recent Developments/Updates

Table 134. ADMA Biologics Competitive Strengths & Weaknesses

Table 135. Grand Shuyang Basic Information, Manufacturing Base and Competitors

Table 136. Grand Shuyang Major Business

Table 137. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 138. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 139. Grand Shuyang Recent Developments/Updates

Table 140. Grand Shuyang Competitive Strengths & Weaknesses

Table 141. PAFC Basic Information, Manufacturing Base and Competitors

Table 142. PAFC Major Business

Table 143. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 144. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 145. PAFC Recent Developments/Updates

Table 146. PAFC Competitive Strengths & Weaknesses

Table 147. Weiguang Biological Products Basic Information, Manufacturing Base and Competitors

Table 148. Weiguang Biological Products Major Business

Table 149. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 150. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 151. Weiguang Biological Products Recent Developments/Updates

Table 152. Weiguang Biological Products Competitive Strengths & Weaknesses

Table 153. Beijing Bohui Innovation Biotechnology Basic Information, Manufacturing Base and Competitors

- Table 154. Beijing Bohui Innovation Biotechnology Major Business
- Table 155. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 156. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 157. Beijing Bohui Innovation Biotechnology Recent Developments/Updates
- Table 158. Beijing Bohui Innovation Biotechnology Competitive Strengths & Weaknesses
- Table 159. CSL Behring Basic Information, Manufacturing Base and Competitors
- Table 160. CSL Behring Major Business
- Table 161. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 162. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 163. CSL Behring Recent Developments/Updates
- Table 164. CSL Behring Competitive Strengths & Weaknesses
- Table 165. Takeda Basic Information, Manufacturing Base and Competitors
- Table 166. Takeda Major Business
- Table 167. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 168. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 169. Takeda Recent Developments/Updates
- Table 170. Takeda Competitive Strengths & Weaknesses
- Table 171. Grifols Basic Information, Manufacturing Base and Competitors
- Table 172. Grifols Major Business
- Table 173. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product and Services
- Table 174. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 175. Grifols Recent Developments/Updates
- Table 176. Grifols Competitive Strengths & Weaknesses
- Table 177. Octapharma Basic Information, Manufacturing Base and Competitors
- Table 178. Octapharma Major Business
- Table 179. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection

## Product and Services

Table 180. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 181. Octapharma Recent Developments/Updates

Table 182. Octapharma Competitive Strengths & Weaknesses

Table 183. Bio Products Laboratory Basic Information, Manufacturing Base and Competitors

Table 184. Bio Products Laboratory Major Business

Table 185. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 186. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 187. Bio Products Laboratory Recent Developments/Updates

Table 188. Bio Products Laboratory Competitive Strengths & Weaknesses

Table 189. Kedrion Basic Information, Manufacturing Base and Competitors

Table 190. Kedrion Major Business

Table 191. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 192. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 193. Kedrion Recent Developments/Updates

Table 194. Kedrion Competitive Strengths & Weaknesses

Table 195. LFB Basic Information, Manufacturing Base and Competitors

Table 196. LFB Major Business

Table 197. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 198. LFB Human Immumoglobulin (PH4) for Intravenous Injection Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 199. LFB Recent Developments/Updates

Table 200. LFB Competitive Strengths & Weaknesses

Table 201. GC Biopharma Basic Information, Manufacturing Base and Competitors

Table 202. GC Biopharma Major Business

Table 203. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product and Services

Table 204. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection

Production (Tons), Price (US\$/g), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 205. GC Biopharma Recent Developments/Updates

Table 206. GC Biopharma Competitive Strengths & Weaknesses

Table 207. Global Key Players of Human Immumoglobulin (PH4) for Intravenous Injection Upstream (Raw Materials)

Table 208. Global Human Immumoglobulin (PH4) for Intravenous Injection Typical Customers

Table 209. Human Immumoglobulin (PH4) for Intravenous Injection Typical Distributors

## List Of Figures

### LIST OF FIGURES

- Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Picture
- Figure 2. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value: 2021 & 2025 & 2032, (USD Million)
- Figure 3. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value and Forecast (2021-2032) & (USD Million)
- Figure 4. World Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 5. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price (2021-2032) & (US\$/g)
- Figure 6. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Region (2021-2032)
- Figure 7. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Region (2021-2032)
- Figure 8. North America Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 9. Europe Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 10. China Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 11. Japan Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 12. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 13. India Human Immumoglobulin (PH4) for Intravenous Injection Production (2021-2032) & (Tons)
- Figure 14. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
- Figure 15. Factors Affecting Demand
- Figure 16. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
- Figure 17. World Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share by Region (2021-2032)
- Figure 18. United States Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)
- Figure 19. China Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)

Figure 20. Europe Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)

Figure 21. Japan Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)

Figure 22. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)

Figure 23. ASEAN Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)

Figure 24. India Human Immumoglobulin (PH4) for Intravenous Injection Consumption (2021-2032) & (Tons)

Figure 25. Producer Shipments of Human Immumoglobulin (PH4) for Intravenous Injection by Manufacturer Revenue (\$MM) and Market Share (%): 2025

Figure 26. Global Four-firm Concentration Ratios (CR4) for Human Immumoglobulin (PH4) for Intravenous Injection Markets in 2025

Figure 27. Global Four-firm Concentration Ratios (CR8) for Human Immumoglobulin (PH4) for Intravenous Injection Markets in 2025

Figure 28. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share Comparison (2021 & 2025 & 2032)

Figure 30. United States VS China: Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share Comparison (2021 & 2025 & 2032)

Figure 31. United States Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025

Figure 32. China Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025

Figure 33. Rest of World Based Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share 2025

Figure 34. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Concentration, (USD Million), 2021 & 2025 & 2032

Figure 35. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Concentration in 2025

Figure 36. 5%

Figure 37. 10%

Figure 38. 20%

Figure 39. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Concentration (2021-2032)

Figure 40. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Concentration (2021-2032)

Figure 41. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Concentration (2021-2032) & (US\$/g)

Figure 42. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Source Plasma Screening Standard, (USD Million), 2021 & 2025 & 2032

Figure 43. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Source Plasma Screening Standard in 2025

Figure 44. Standard-Qualified Plasma

Figure 45. High-Safety Plasma

Figure 46. Special-Indication

Figure 47. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Source Plasma Screening Standard (2021-2032)

Figure 48. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Source Plasma Screening Standard (2021-2032)

Figure 49. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Source Plasma Screening Standard (2021-2032) & (US\$/g)

Figure 50. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Production Process, (USD Million), 2021 & 2025 & 2032

Figure 51. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Production Process in 2025

Figure 52. Cohn-Fractionation

Figure 53. Chromatography-Purified

Figure 54. Ultrafiltration-Refined

Figure 55. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Production Process (2021-2032)

Figure 56. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Production Process (2021-2032)

Figure 57. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Production Process (2021-2032) & (US\$/g)

Figure 58. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 59. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Application in 2025

Figure 60. Immunodeficiency Disease

Figure 61. Autoimmune Disease

Figure 62. Severe Infectious Disease

Figure 63. World Human Immumoglobulin (PH4) for Intravenous Injection Production Market Share by Application (2021-2032)

Figure 64. World Human Immumoglobulin (PH4) for Intravenous Injection Production Value Market Share by Application (2021-2032)

Figure 65. World Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Application (2021-2032) & (US\$/g)

Figure 66. Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain

Figure 67. Human Immumoglobulin (PH4) for Intravenous Injection Procurement Model

Figure 68. Human Immumoglobulin (PH4) for Intravenous Injection Sales Model

Figure 69. Human Immumoglobulin (PH4) for Intravenous Injection Sales Channels, Direct Sales, and Distribution

Figure 70. Methodology

Figure 71. Research Process and Data Source

## I would like to order

Product name: Global Human Immumoglobulin (PH4) for Intravenous Injection Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G26A768DCD86EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G26A768DCD86EN.html>